Skip to content

Faeth Therapeutics Inc FTH Stock Analysis

  • Nasdaq
  • Stock
  • Market open · no trades yet today

$18.69 down $0.06, 0.32% at close Oct 30

Last close · Previous close $18.75

Market cap
At the Oct 30 close
P/E ratio
On last 12 months’ EPS
Diluted EPS
Last 12 months
Dividend yield
Last 12 months

Price chart

$18.69down $0.06, 0.32%Fri, Oct 30 session

Use the left and right arrow keys to move along the chart.

Chart period
IEX trades, regular session · Times in ET
Price data

Trading

At last close

  • Previous close$18.75Oct 29
Member SIPC.Low CommissionsLearn More (opens in a new tab)

Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.

Performance

Valuation

Financials

Dividends

About Faeth Therapeutics Inc

Sensei Biotherapeutics is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable checkpoints and other immunosuppressive signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei’s lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also developing SNS-102, a conditional binding monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4), as well as SNS-103, also a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), also known as CD39.

Sector
Industry
Headquarters
Exchange
Nasdaq
Asset type
Common stock
Price history since

FTH news

FTH stock FAQ

What is FTH stock’s price today?

Faeth Therapeutics (FTH) traded at $18.69 at the close on , down $0.06 (0.32%) from the previous close of $18.75.

What exchange does FTH trade on?

Faeth Therapeutics trades on the Nasdaq under the ticker symbol FTH. Its price history on this dashboard begins on .

Member SIPC.Low CommissionsLearn More (opens in a new tab)

Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.

About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.

This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).

The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.

Contact Ryan

Get in touch

Contact Me

Have a question or want to work together? Fill out the form below and we'll get back to you as soon as possible.

Contact Form Demo

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.